These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36652763)

  • 41. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs.
    Zhao J; Ye H; Lu Q; Wang K; Chen X; Song J; Wang H; Lu Y; Cheng M; He Z; Zhai Y; Zhang H; Sun J
    J Nanobiotechnology; 2022 Feb; 20(1):62. PubMed ID: 35109878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer.
    Li B; Yang T; Liu J; Yu X; Li X; Qin F; Zheng J; Liang J; Zeng Y; Zhou Z; Liu L; Zhang B; Yao W; Feng Z; Zeng G; Zhou Q; Chen L
    Acta Biomater; 2023 Apr; 161():184-200. PubMed ID: 36893957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer.
    Li L; Wang J; Radford DC; Kopeček J; Yang J
    J Control Release; 2021 Apr; 332():652-659. PubMed ID: 33607175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
    Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
    Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
    Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
    J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
    Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
    Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.
    Tang H; Wang Y; Chlewicki LK; Zhang Y; Guo J; Liang W; Wang J; Wang X; Fu YX
    Cancer Cell; 2016 Mar; 29(3):285-296. PubMed ID: 26977880
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ginsenoside Rg3 nanoparticles with permeation enhancing based chitosan derivatives were encapsulated with doxorubicin by thermosensitive hydrogel and anti-cancer evaluation of peritumoral hydrogel injection combined with PD-L1 antibody.
    Wu H; Wei G; Luo L; Li L; Gao Y; Tan X; Wang S; Chang H; Liu Y; Wei Y; Song J; Zhang Z; Huo J
    Biomater Res; 2022 Dec; 26(1):77. PubMed ID: 36494759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic Delivery of mPEG-Masked Trispecific T-Cell Nanoengagers in Synergy with STING Agonists Overcomes Immunotherapy Resistance in TNBC and Generates a Vaccination Effect.
    Shen M; Chen C; Guo Q; Wang Q; Liao J; Wang L; Yu J; Xue M; Duan Y; Zhang J
    Adv Sci (Weinh); 2022 Nov; 9(32):e2203523. PubMed ID: 36089659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thermal-sensitive lipid nanoparticles potentiate anti-PD therapy through enhancing drug penetration and T lymphocytes infiltration in metastatic tumor.
    Tan YN; Li YP; Huang JD; Luo M; Li SS; Lee AW; Hu FQ; Guan XY
    Cancer Lett; 2021 Dec; 522():238-254. PubMed ID: 34571084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
    Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
    Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GE11-modified carboxymethyl chitosan micelles to deliver DOX·PD-L1 siRNA complex for combination of ICD and immune escape inhibition against tumor.
    Song P; Wang B; Pan Q; Jiang T; Chen X; Zhang M; Tao J; Zhao X
    Carbohydr Polym; 2023 Jul; 312():120837. PubMed ID: 37059562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
    Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
    Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
    ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Firing up the cold tumors by targeting Vps34.
    Janji B; Hasmim M; Parpal S; Berchem G; Noman MZ
    Oncoimmunology; 2020 Aug; 9(1):1809936. PubMed ID: 32939326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
    Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
    Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.